Susquehanna International Group
GANX icon

Susquehanna International Group’s Gain Therapeutics GANX Stock Holding History

Susquehanna International Group’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$159K Sell
78,206
-353,061
-82% -$651K ﹤0.01% 12157
2026
Q1 		$837K Sell
431,267
-253,082
-37% -$551K ﹤0.01% 8369
2025
Q4 		$2.2M Buy
684,349
+603,914
+751% +$1.61M ﹤0.01% 5449
2025
Q3 		$142K Buy
80,435
+884
+1% +$1.49K ﹤0.01% 11321
2025
Q2 		$143K Sell
79,551
-6,407
-7% -$11.8K ﹤0.01% 11533
2025
Q1 		$164K Buy
85,958
+39,045
+83% +$86.6K ﹤0.01% 11137
2024
Q4 		$101K Buy
+46,913
New +$94.2K ﹤0.01% 11337
2024
Q2 		– Sell
-43,062
Closed -$162K – 12429
2024
Q1 		$162K Buy
43,062
+8,562
+25% +$35.5K ﹤0.01% 10829
2023
Q4 		$113K Sell
34,500
-30,726
-47% -$85.4K ﹤0.01% 11228
2023
Q3 		$211K Sell
65,226
-4,564
-7% -$17.3K ﹤0.01% 10121
2023
Q2 		$313K Buy
69,790
+54,618
+360% +$267K ﹤0.01% 9347
2023
Q1 		$73.1K Buy
+15,172
New +$62K ﹤0.01% 11508
2022
Q1 		– Sell
-19,357
Closed -$103K – 13332
2021
Q4 		$103K Buy
+19,357
New +$134K ﹤0.01% 12127

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group's GANX Position: Q2 2026 in Review

Susquehanna International Group reduced its Gain Therapeutics (GANX) stake by 82% in Q2 2026, selling an estimated $651K and leaving 78,206 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #12157.

Susquehanna International Group first reported a position in GANX in Q4 2021 and has held it in 13 quarters since. The position peaked at $2.2M in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Susquehanna International Group held 78,206 shares of Gain Therapeutics worth $159K as of Q2 2026.
  • Susquehanna International Group sold 353,061 Gain Therapeutics shares in Q2 2026, an estimated $651K.
  • Gain Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #12157 holding.
  • Susquehanna International Group first reported a position in Gain Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • Susquehanna International Group's Gain Therapeutics position peaked at $2.2M in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.